Relay Therapeutics to Participate in Two Upcoming Investor Conferences in November

Rhea-AI Summary

Relay Therapeutics (Nasdaq: RLAY) announced management will participate in two investor fireside chats in November 2025. Guggenheim’s 2nd Annual Healthcare Innovation Conference is scheduled for Monday, November 10, 2025 at 11:00–11:25 a.m. ET. Jefferies 2025 Global Healthcare Conference is scheduled for Wednesday, November 19, 2025 at 11:30–11:55 a.m. ET (4:30–4:55 p.m. GMT).

The sessions will be webcast live and accessible via Relay Therapeutics’ investor Events page at https://ir.relaytx.com/news-events/events-presentations. An archived replay will be available for up to 30 days after each event.

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in November:

• Guggenheim’s 2^nd Annual Healthcare Innovation Conference on Monday, November 10, 2025 at 11:00-11:25 a.m. ET
• Jefferies 2025 Global Healthcare Conference on Wednesday, November 19, 2025 at 11:30-11:55 a.m. ET (4:30-4:55 p.m. GMT)
  
  

The fireside chats will be webcast live and may be accessed through Relay Therapeutics’ website under Events in the News & Events section through the following link: https://ir.relaytx.com/news-events/events-presentations. An archived replay of the webcast will be available for up to 30 days following the event.

About Relay Therapeutics

Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. Relay's Dynamo^® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The company’s lead clinical asset, RLY-2608, is the first pan-mutant selective PI3Kα inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. RLY-2608 is also being investigated in a group of genetic disease indications called PI3Kα-driven vascular malformations. Relay's pipeline also includes late-stage research programs for NRAS-driven solid tumors and Fabry disease. For more information, please visit www.relaytx.com or follow us on LinkedIn.

Contact:
Pete Rahmer
prahmer@relaytx.com

Media:
Dan Budwick
1AB
973-271-6085
dan@1abmedia.com

FAQ

When will Relay Therapeutics (RLAY) present at Guggenheim’s 2nd Annual Healthcare Innovation Conference?

Relay will present on Monday, November 10, 2025 from 11:00–11:25 a.m. ET.

When is Relay Therapeutics (RLAY) scheduled to speak at the Jefferies 2025 Global Healthcare Conference?

Relay is scheduled for Wednesday, November 19, 2025 from 11:30–11:55 a.m. ET (4:30–4:55 p.m. GMT).

How can investors watch the Relay Therapeutics (RLAY) fireside chats live?

The fireside chats will be webcast live and can be accessed via Relay’s investor Events page at https://ir.relaytx.com/news-events/events-presentations.

Will Relay Therapeutics (RLAY) make replays of the investor presentations available?

Yes. An archived replay of each webcast will be available for up to 30 days following the event.

What topics will Relay Therapeutics (RLAY) management cover in the November 2025 fireside chats?

Management will discuss recent company developments and outlook during the fireside chats, as presented in the webcast sessions.

Where can I find the exact webcast links and event times for Relay Therapeutics (RLAY)?

Exact webcast links and event details are posted on Relay’s investor News & Events page at https://ir.relaytx.com/news-events/events-presentations.